Arca
Skip to content
Tools
Tools

Epi-Caine, Epinephrine 0.025% Lidocaine HCL 0.75% Solution for Intraocular Injection

Recall D-0130-2023, part of FDA recall event 91378. See Pine Pharmaceuticals's company page.

Pine Pharmaceuticals, LLC started this Class II drug recall on Dec 22, 2022 (voluntary: firm initiated); FDA lists it as terminated, terminated May 4, 2023.

  • Classification: Class II
  • Started: Dec 22, 2022
  • Status: Terminated

Why It Was Recalled

Class II

CGMP Deviations: Raw material recalled by repackager, due to discoloration.

Record

Product
Epi-Caine, Epinephrine 0.025% Lidocaine HCL 0.75% Solution for Intraocular Injection, 1 ml, Single Dose Vial, Compounded by Pine Pharmaceuticals, 355 Riverwalk Pkwy, Tonawanda, NY 14150. NDC 69194-0948-1
Quantity
11,453 vials
Lots and codes
Lot # 62881, Exp 12/25/2022; 62923, Exp 12/26/2022; 63066, Exp 01/03/2023; 63067, Exp 01/01/2023; 63103, Exp 01/02/2023; 63120, Exp 01/03/2023; 63219, 63226, Exp 01/08/2023; 63263, Exp 01/09/2023; 63380, 63381, Exp 01/15/2023; 63433, Exp 01/16/2023; 63455, Exp 01/17/2023; 63537, Exp 01/22/2023; 63580, Exp 01/23/2023; 63721, Exp 01/29/2023; 63792, Exp 01/31/2023; 63888, Exp 02/05/2023; 63930, Exp 02/06/2023; 63959, Exp 02/07/2023; 64079, Exp 02/13/2023; 64109, Exp 02/14/2023; 64239, Exp 02/21/2023.
Distribution
Nationwide to medical facilities.
Recalling firm
Pine Pharmaceuticals, LLC, Tonawanda, NY, United States
How the firm notified
E-Mail
FDA classified
Jan 13, 2023

Pine Pharmaceuticals, LLC's Other Recalls

Newest first, one product per recall event; search them all

FDA's weekly Enforcement Report, as openFDA publishes it. A recall is classified by how likely the product is to cause harm: Class I is the most serious. openFDA drug enforcement reports

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.